| Literature DB >> 35111798 |
Estelle Strydom1, Lizelle Zandberg1, Erna T Kemp1, Philip vZ Venter2, Cornelius M Smuts1, Herculina S Kruger1, Jeannine Baumgartner1,3.
Abstract
Both iron and omega-3 (n-3) polyunsaturated fatty acids may play an important role in bone development. The aim of this study was to investigate the effects of pre- and post-natal iron and n-3 fatty acid deficiency (FAD), alone and in combination, on bone development in rats, and to determine whether effects are reversible when a sufficient diet is provided post-weaning. Using a 2×2-factorial design, 56 female Wistar rats were allocated to one of four diets: (1) control, (2) iron deficient (ID), (3) n-3 FAD or (4) ID and n-3 FAD, and were maintained on the respective diets throughout gestation and lactation. At weaning (post-natal day [PND] 21), offspring (n = 24/group; male:female=1:1) were randomly allocated to either continue with their respective diets or to switch to the control diet until PND 42-45. Bone mineral density (BMD) and bone strength were determined using dual X-ray absorptiometry and three-point bending tests, respectively. Pre- and post-natal ID resulted in significantly lower BMD in the spine and bone strength in the left femur. Both ID and n-3 FAD resulted in lower BMD in the right femur, with an additive reduction in the combined ID and n-3 FAD group vs. controls. While negative effects of pre- and post-natal ID alone were reversed in offspring switched to a control diet post-weaning, lower BMD and bone strength persisted in offspring with combined ID and n-3 FAD during the prenatal and early post-natal period. Effects were not sex-specific. These results indicate that ID during early life may negatively influence bone development, with potential additive effects of n-3 FAD. While the effects of ID alone seem reversible, a combined ID and n-3 FAD may result in irreversible deficits in bone development.Entities:
Keywords: bone development; bone mineral density; bone strength; iron; omega-3 polyunsaturated fatty acid (n-3 PUFA)
Year: 2022 PMID: 35111798 PMCID: PMC8801778 DOI: 10.3389/fnut.2021.802609
Source DB: PubMed Journal: Front Nutr ISSN: 2296-861X
Figure 1Schematic diagram of the experimental design. n, number of rats; PND, post-natal day; ID, iron deficiency; n-3 FAD, omega-3 fatty acid deficiency; *equal male:female ratio.
Offspring body weight, iron, and n and omega-3 fatty acid status at post-natal day 42–45.
|
|
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| |
| Body weight (g) | 190 ± 1.0a | 24 | 172 ± 1.0ab | 24 | 188 ± 1.0a | 24 | 157 ± 1.0b | 24 | <0.001 | 0.051 | 0.105 |
| Weight gain from PND 21 (g) | 133 ± 1.1a | 24 | 114 ± 1.0bc | 24 | 125 ± 1.0ab | 24 | 105 ± 1.0c | 24 | <0.001 | 0.009 | 0.724 |
| Hemoglobin (g/dL) | 13.4 ± 1.0a | 24 | 9.3 ± 1.0b | 24 | 12.7 ± 1.0a | 24 | 8.5 ± 1.0b | 23 | <0.001 | 0.044 | 0.582 |
| Liver iron (μg/L) | 142 ± 1.1a | 24 | 27 ± 1.0b | 24 | 169 ± 1.2a | 22 | 26 ± 1.1b | 24 | <0.001 | 0.436 | 0.250 |
| Plasma ferritin (ng/mL) | 138 ± 1.3 | 11 | 121 ± 1.1 | 11 | 192 ± 1.5 | 11 | 193 ± 1.2 | 12 | 0.817 | 0.119 | 0.839 |
| RBC n-3 FA (% total FA) | 7.7 ± 1.0a | 24 | 7.6 ± 1.0a | 23 | 1.7 ± 1.0b | 24 | 1.8 ± 1.1b | 24 | 0.398 | <0.001 | 0.213 |
| RBC n-6 FA (% total FA) | 42.6 ± 1.0c | 24 | 42.2 ± 1.0c | 23 | 48.9 ± 1.0a | 24 | 47.0 ± 1.0b | 24 | 0.003 | <0.001 | 0.071 |
| RBC n-6/n-3 FA (% total FA) | 6.3 ± 1.0b | 24 | 6.4 ± 1.0b | 23 | 79.2 ± 1.1a | 24 | 65.3 ± 1.1a | 24 | 0.264 | <0.001 | 0.223 |
|
|
|
|
| ||||||||
| Body weight (g) | 190 ± 1.0a | 24 | 184 ± 1.0ab | 24 | 196 ± 1.0a | 23 | 169 ± 1.0b | 24 | <0.001 | 0.377 | 0.014 |
| Weight gain from PND 21 (g) | 133 ± 1.1a | 24 | 127 ± 1.0ab | 24 | 127 ± 1.0ab | 23 | 114 ± 1.1b | 24 | 0.007 | 0.020 | 0.300 |
| Hemoglobin (g/dL) | 13.4 ± 1.0 | 24 | 13.7 ± 1.0 | 24 | 13.7 ± 1.0 | 22 | 13.7 ± 1.0 | 22 | 0.610 | 0.819 | 0.766 |
| Liver iron (μg/L) | 142 ± 1.1 | 24 | 140 ± 1.2 | 24 | 142 ± 1.2 | 23 | 94 ± 1.1 | 21 | 0.090 | 0.134 | 0.031 |
| Plasma ferritin (ng/mL) | 138 ± 1.3 | 11 | 193 ± 1.4 | 11 | 217 ± 1.3 | 12 | 282 ± 1.4 | 11 | 0.218 | 0.123 | 0.859 |
| RBC n-3 FA (% total FA) | 7.7 ± 1.0a | 24 | 7.9 ± 1.1a | 21 | 6.0 ± 1.0b | 22 | 5.9 ± 1.0b | 20 | 0.987 | <0.001 | 0.659 |
| RBC n-6 FA (% total FA) | 42.6 ± 1.0bc | 24 | 41.7 ± 1.0c | 20 | 44.9 ± 1.0a | 22 | 43.6 ± 1.0b | 22 | <0.001 | <0.001 | 0.582 |
| RBC n-6/n-3 FA (% total FA) | 6.3 ± 1.0b | 24 | 5.6 ± 1.0b | 19 | 9.0 ± 1.0a | 22 | 8.9 ± 1.0a | 20 | 0.097 | <0.001 | 0.154 |
Two-way ANCOVA was used to test effects of ID, n-3 FAD, and ID x n-3 FAD interactions, adjusted for sex. All parameters were log transformed to perform ANCOVA. Between-group differences were determined using one-way ANCOVA followed by Bonferroni's post-hoc test (adjusted for sex). Values are unadjusted geometric means ± SEM for log transformed variables. Means in a row with superscripts without a common letter differ (P < 0.05).
ID, iron deficiency; n-3 FAD, omega-3 fatty acid deficiency; FA, fatty acids; n-6 FA, omega-6 fatty acids; PND, post-natal day; RBC, red blood cell.
Figure 2Lumbar spine and right femur bone mineral density. Two-way ANCOVA was used to test effects of ID, n-3 FAD, and ID x n-3 FAD interactions, adjusted for sex and body weight. Spine and right femur BMD were log transformed to perform ANCOVA. Between-group differences were determined using one-way ANCOVA followed by Bonferroni's post-hoc test (adjusted for sex and body weight). Values are unadjusted geometric means ± SEM for log transformed variables. Means with superscripts without a common (capital or small) letter differ (P < 0.05). ID, iron deficiency; n-3 FAD, omega-3 fatty acid deficiency; BMD, bone mineral density.
Left femur size and bone strength indicators in offspring at post-natal day 42–45.
|
| |||||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| |
| Femur weight (mg) | 609 ± 17ab | 569 ± 23ab | 614 ± 14a | 515 ± 17b | 0.604 | 0.628 | 0.001 |
| Femur length (mm) | 17.9 ± 1.01 | 17.8 ± 1.02 | 17.7 ± 1.01 | 17.0 ± 1.01 | 0.752 | 0.057 | 0.069 |
| Femur area (mm2) | 4.3 ± 0.1 | 4.1 ± 0.1 | 4.0 ± 0.1 | 3.8 ± 0.1 | 0.036 | 0.505 | 0.745 |
| Stiffness (N/mm) | 114.7 ± 8ab | 80.2 ± 7ab | 110.5 ± 6a | 72.2 ± 6b | 0.003 | 0.554 | 0.716 |
| Ultimate load (N) | 43.2 ± 1.7a | 32.4 ± 1.6b | 42.4 ± 1.2a | 31.2 ± 1.2b | <0.001 | 0.884 | 0.659 |
| Transition load (N) | 31.4 ± 1.6 | 22.5 ± 1.4 | 30.9 ± 1.4 | 21.9 ± 1.5 | 0.011 | 0.754 | 0.720 |
| Ultimate displacement (mm) | 0.76 ± 0.04 | 0.80 ± 0.03 | 0.86 ± 0.04 | 0.86 ± 0.06 | 0.089 | 0.011 | 0.549 |
| Transition displacement (mm) | 0.30 ± 0.03 | 0.32 ± 0.04 | 0.30 ± 0.02 | 0.33 ± 0.03 | 0.158 | 0.607 | 0.966 |
| Ultimate stress (MPa) | 10.0 ± 1.1a | 7.9 ± 1.0b | 10.5 ± 1.0a | 8.2 ± 1.0b | <0.001 | 0.559 | 0.812 |
| Transition stress (MPa) | 7.3 ± 0.35ab | 5.6 ± 0.42b | 7.8 ± 0.47a | 5.8 ± 0.39b | 0.004 | 0.492 | 0.574 |
|
|
|
|
| ||||
| Femur weight (mg) | 609 ± 17ab | 633 ± 23a | 620 ± 13a | 528 ± 19b | 0.692 | 0.108 | <0.001 |
| Femur length (mm) | 17.9 ± 0.1a | 17.8 ± 0.2ab | 17.7 ± 0.1ab | 17.2 ± 0.1b | 0.047 | 0.017 | 0.237 |
| Femur area (mm2) | 4.3 ± 0.1 | 4.1 ± 0.1 | 4.0 ± 0.1 | 3.7 ± 0.1 | 0.853 | 0.165 | 0.120 |
| Stiffness (N/mm) | 114.7 ± 8a | 111.6 ± 12a | 111.5 ± 7a | 62.3 ± 8b | 0.003 | 0.001 | 0.003 |
| Ultimate load (N) | 43.2 ± 1.7a | 40.0 ± 1.3a | 41.3 ± 1.4a | 30.7 ± 1.9b | 0.003 | 0.007 | 0.057 |
| Transition load (N) | 31.4 ± 1.6 | 30.0 ± 2.0 | 28.8 ± 1.7 | 21.7 ± 1.4 | 0.321 | 0.053 | 0.382 |
| Ultimate displacement (mm) | 0.76 ± 0.04 | 0.71 ± 0.04 | 0.86 ± 0.04 | 0.85 ± 0.04 | 0.775 | 0.003 | 0.491 |
| Transition displacement (mm) | 0.30 ± 0.03b | 0.34 ± 0.05ab | 0.28 ± 0.02b | 0.40 ± 0.05a | 0.005 | 0.138 | 0.082 |
| Ultimate stress (MPa) | 10.0 ± 1.1a | 9.8 ± 1.0a | 10.3 ± 1.0a | 8.0 ± 1.1b | 0.006 | 0.031 | 0.005 |
| Transition stress (MPa) | 7.3 ± 0.35 | 7.4 ± 0.45 | 7.2 ± 0.41 | 5.9 ± 0.46 | 0.354 | 0.138 | 0.158 |
Two-way ANCOVA was used to test effects of ID, n-3 FAD and ID x n-3 FAD interactions, adjusted for sex and body weight. Femur length and ultimate stress were log transformed to perform ANCOVA. Between-group differences were determined using one-way ANCOVA followed by Bonferroni's post-hoc test (adjusted for sex and body weight). Means in a row with superscripts without a common letter differ (P < 0.05). Values are unadjusted means ± SEM or geometric means ± SEM for log transformed variables. (Control, n = 15; ID/ID, n = 12; n-3 FAD/n-3 FAD, n = 19; ID+n-3 FAD/ID+n-3 FAD, n = 13; ID/Control, n = 14; n-3 FAD/Control, n = 20; ID+n-3 FAD, n = 12). ID, iron deficiency; n-3 FAD, omega-3 fatty acid deficiency; BMD, bone mineral density.
Figure 3Insulin-like growth factor-1. Two-way ANCOVA was used to test effects of ID, n-3 FAD, and ID x n-3 FAD interactions, adjusted for sex and body weight. IGF-1 was log transformed to perform ANCOVA. Between-group differences were determined using one-way ANCOVA followed by Bonferroni's post-hoc test (adjusted for sex and body weight). Means with superscripts without a common letter differ (P < 0.05). ID, iron deficiency; n-3 FAD, omega-3 fatty acid deficiency; IGF-1, insulin-like growth factor-1.